<- Go Home
Mind Medicine (MindMed) Inc.
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Market Cap
$725.3M
Volume
1.2M
Cash and Equivalents
$295.3M
EBITDA
N/A
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$12.22
52 Week Low
$4.46
Dividend
N/A
Price / Book Value
3.08
Price / Earnings
-6.02
Price / Tangible Book Value
3.33
Enterprise Value
$454.3M
Enterprise Value / EBITDA
N/A
Operating Income
-$93.7M
Return on Equity
54.61%
Return on Assets
-25.38
Cash and Short Term Investments
$295.3M
Debt
$24.3M
Equity
$262.2M
Revenue
N/A
Unlevered FCF
-$39.7M
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium